Clinical Characteristics and Neurodevelopmental Outcome in Children with Congenital Hyperinsulinism in Resource Limited Settings
Abstract
This study was conducted to describe the clinical characteristics of persistent Congenital Hyperinsulinism (CHI) and evaluate neurodevelopmental outcome and its risk factors in a cohort of Pakistani children.
This was a cohort observational analytical study carried out at the Pediatric Endocrinology Department, The University of Child Health Sciences, The Children’s Hospital Lahore. Total 29 patients fulfilling the inclusion criteria were included in the study. Biochemical profile was recorded including serum insulin levels, C-peptide level, blood or urinary ketones. All children had their first assessment at the time of enrolment in study. Further follow up and neurodevelopment assessment was done at 6 months and one year after the first visit. Neurological assessment was done by the neurologist using TINE score (Touwen Infant Neurological Examination) for children who are younger than 2 years and by Hadders-Algra score for older children.
Among children 65.6% presented with early onset of disease (<30 days) and with severe disease, 58.6% children were treated with octreotide while the remaining 34.48% children were treated with oral diazoxide. None of the children underwent surgical treatment. Abnormal neurological examination was noted in 55.17% children, 16.67% children had abnormal EEG findings, 33.3% children echocardiography findings were abnormal, as suffering from congenital heart disease, and 18.18% of children MRI findings were abnormal. Children with abnormal neurological assessment had severe disease, delayed referral to tertiary care hospital, longer admission duration, high frequency of worse symptoms, high frequency of abnormal EEG and MRI findings.
The prompt management of newborn hypoglycemia is essential for the fruitful outcome. Improving healthcare personnel knowledge and comprehension care of newborn hypoglycemia, implementing standardized neurodevelopmental testing, and determining causal relationship of congenital heart disease in CHI is necessary.
How to Cite This Article
Khan MA, Manzoor J, Zahid M, Alvi JR, Afzal MS, Aftab S. Clinical Characteristics and Neurodevelopmental Outcome in Children with Congenital Hyperinsulinism in Resource Limited Settings. J Pak Soc Intern Med. 2025;6(4):340–347. doi:10.70302/jpsim.v6i4.2563
Conflict of Interest
All authors declare no competing interests.
Funding
No specific funding was received for this research.
Funder information follows the Crossref Funder Registry standard.
References
- Kostopoulou E, Shah P. Hyperinsulinaemic hypoglycaemia—an overview of a complex clinical condition. Eu J Pediat. 2019;178:1151-60.
- Ludwig A, Ziegenhorn K, Empting S, Meissner T, Marquard J, Holl R, et al., editors. Glucose metabolism and neurological outcome in congenital hyperinsulinism. Seminars in pediatric surgery; 2011: Elsevier.
- Yorifuji T. Congenital hyperinsulinism: current status and future perspectives. Annals of Pediat Endocrinol Metabol. 2014;19(2):57.
- Rozenkova K, Malikova J, Nessa A, Dusatkova L, Bjørkhaug L, Obermannova B, et al. High incidence of heterozygous ABCC8 and HNF1A mutations in Czech patients with congenital hyperinsulinism. J Clin Endocrinol Metabol. 2015;100(12):E1540-E9.
- De Leon DD, Arnoux JB, Banerjee I, Bergada I, Bhatti T, Conwell LS, et al. International guidelines for the diagnosis and management of hyperinsulinism. Hormone Res Paediatr. 2024;97(3):279-98.
- Rosenfeld E, Ganguly A, De Leon DD, editors. Congenital hyperinsulinism disorders: genetic and clinical characteristics. Am J Med Genet. 2019;181(4):682-92.
- Hewat TI, Johnson MB, Flanagan SE. Congenital hyperinsulinism: current laboratory-based approaches to the genetic diagnosis of a heterogeneous disease. Front Endocrinol. 2022;13:873254.
- Giri D, Hawton K, Senniappan S. Congenital hyperinsulinism: recent updates on molecular mechanisms, diagnosis and management. J Pediatr Endocrinol Metabol. 2022;35(3):279-96.
- Banerjee I, Salomon‐Estebanez M, Shah P, Nicholson J, Cosgrove K, Dunne M. Therapies and outcomes of congenital hyperinsulinism‐induced hypoglycaemia. Diab Med. 2019;36(1):9-21.
- Muukkonen L, Männistö J, Jääskeläinen J, Hannonen R, Huopio H. The effect of hypoglycaemia on neurocognitive outcome in children and adolescents with transient or persistent congenital hyperinsulinism. Development Med Child Neurol. 2019;61(4):451-7.
- Ludwig A, Enke S, Heindorf J, Empting S, Meissner T, Mohnike K. Formal neurocognitive testing in 60 patients with congenital hyperinsulinism. Hormone Res Paediatr. 2018;89(1):1-6.
- Kumaran A, Kar S, Kapoor RR, Hussain K. The clinical problem of hyperinsulinemic hypoglycemia and resultant infantile spasms. Pediatrics. 2010;126(5):e1231-e6.
- Mutter CM, Smith T, Menze O, Zakharia M, Nguyen H. Diabetes insipidus: pathogenesis, diagnosis, and clinical management. Cureus. 2021;13(2):e13523.
- Salomon-Estebanez M, Mohamed Z, Michaelidou M, Collins H, Rigby L, Skae M, et al. Vineland adaptive behavior scales to identify neurodevelopmental problems in children with Congenital Hyperinsulinism (CHI). Orphanet J Rare Dis. 2017;12(1):96.
- Laimon W, Aboelenin HM, El Tantawi NT. Clinical characteristics, outcome, and predictors of neurological sequelae of persistent congenital hyperinsulinism: A single tertiary center experience. Pediatr Diab. 2021;22(3):388-99.
- Rasmussen AG, Melikian M, Globa E, Detlefsen S, Rasmussen L, Petersen H, et al. The difficult management of persistent, non‐focal congenital hyperinsulinism: A retrospective review from a single, tertiary center. Pediatr Diab. 2020;21(3):441-55.
- Xu A, Cheng J, Sheng H, Wen Z, Lin Y, Zhou Z, et al. Clinical management and gene mutation analysis of children with congenital hyperinsulinism in south China. J Clin Res Pediatr Endocrinol. 2019;11(4):400.
- Helleskov A, Melikyan M, Globa E, Shcherderkina I, Poertner F, Larsen A-M, et al. Both low blood glucose and insufficient treatment confer risk of neurodevelopmental impairment in congenital hyperinsulinism: a multinational cohort study. Front Endocrinol. 2017;8:156.
- Demirbilek H, Shah P, Arya VB, Hinchey L, Flanagan SE, Ellard S, et al. Long-term follow-up of children with congenital hyperinsulinism on octreotide therapy. J Clin Endocrinol Metabol. 2014;99(10):3660-7.
- Hu S, Xu Z, Yan J, Liu M, Sun B, Li W, et al. The treatment effect of diazoxide on 44 patients with congenital hyperinsulinism. J Pediatr Endocrinol Metabol. 2012;25(11-12):1119-22.
- Arnoux JB, de Lonlay P, Ribeiro MJ, Hussain K, Blankenstein O, Mohnike K, et al. Congenital hyperinsulinism. Early Human Develop. 2010;86(5):287-94.
- Menni F, De Lonlay P, Sevin C, Touati G, Peigné C, Barbier V, et al. Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia. Pediatrics. 2001;107(3):476-9.
- Meissner T, Wendel U, Burgard P, Schaetzle S, Mayatepek E. Long-term follow-up of 114 patients with congenital hyperinsulinism. Eu J Endocrinol. 2003;149(1):43-51.
- Jack MM, Greer RM, Thomsett MJ, Walker RM, Bell JR, Choong C, et al. The outcome in Australian children with hyperinsulinism of infancy: early extensive surgery in severe cases lowers risk of diabetes. Clin Endocrinol. 2003;58(3):355-64.
- Helleskov A, Melikyan M, Globa E, Shcherderkina I, Poertner F, Larsen A-M, et al. Both Low Blood Glucose and Insufficient Treatment Confer Risk of Neurodevelopmental Impairment in Congenital Hyperinsulinism: A Multinational Cohort Study. Front Endocrinol. 2017;8:156.
Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.